ReviewFrontiers in immunology2020
Familial Mediterranean Fever and COVID-19: Friends or Foes?
Review in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Genetics of symptom remission in outpatients with COVID-19.Scientific reports · 2021Trial
- Plasminogen activator inhibitor-1 genotype 4G/5G associates with skin involvement in Armenian familial Mediterranean fever patients.Rheumatology international · 2024Article
- Two Cases of Familial Mediterranean Fever Involving MEFV Variants: The Importance of Differentiating the Diagnosis from COVID-19.Internal medicine (Tokyo, Japan) · 2023Article
- Is Nuclear Factor Erythroid 2-Related Factor 2 a Target for the Intervention of Cytokine Storms?Antioxidants (Basel, Switzerland) · 2023Review
- Clinical impact and disease evolution of SARS-CoV-2 infection in familial Mediterranean fever.Pharmacological research · 2022Article
- Canakinumab might be Protective against Severe COVID-19 for Patients with Autoinflammatory Disorders.Mediterranean journal of rheumatology · 2022Article
- Hyperinflammation due to COVID-19 and the Targeted Use of Interleukin-1 Inhibitors.Mediterranean journal of rheumatology · 2022Article
- Article
- Noncommunicable diseases, climate change and iniquities: What COVID-19 has taught us about syndemic.European journal of clinical investigation · 2021Review
- Rapid Flow Cytometry-Based Assay for the Functional Classification of MEFV Variants.Journal of clinical immunology · 2021Article
- The impact of COVID-19 on familial Mediterranean fever: a nationwide study.Rheumatology international · 2021Article
- Familial Mediterranean fever and COVID-19. An ancient disease in a pandemic of the new millennium: is it an epiphenomenon of infection?Rheumatology advances in practice · 2021Article
- Role of colchicine in the management of COVID-19 patients: A meta-analysis of cohort and randomized controlled trials.Clinical epidemiology and global healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Familial Mediterranean Fever (FMF) and COVID-19 show a remarkable overlap of clinical symptoms and similar laboratory findings. Both are characterized by fever, abdominal/chest pain, elevation of C-reactive protein, and leukocytosis. In addition, colchicine and IL-1 inhibitors treatments that are effective in controlling inflammation in FMF patients have recently been proposed for off-label use in COVID-19 patients. Thus, FMF may resemble a milder recapitulation of the cytokine storm that is a hallmark of COVID-19 patients progressing to severe disease. We analyzed the sequence of the MEFV-encoded Pyrin protein - whose mutations cause FMF- in mammals, bats and pangolin. Intriguingly, although Pyrin is extremely conserved in species that are considered either a reservoir or intermediate hosts for SARS-CoV-2, some of the most common FMF-causing variants in humans are present as wildtype residues in these species. We propose that in humans, Pyrin may have evolved to fight highly pathogenic infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.